<- Go home

Added to YB: 2024-03-22

Pitch date: 2024-01-23

NTRA [bullish]

Natera, Inc.

+246.19%

current return

Author Info

No bio for this author

Company Info

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Market Cap

$28.2B

Pitch Price

$67.00

Price Target

N/A

Dividend

N/A

EV/EBITDA

-91.38

P/E

-89.19

EV/Sales

12.92

Sector

Biotechnology

Category

growth

Show full summary:
Next Century Growth Investors SMID Cap Growth Strategy New Portfolio holding: Natera, Inc.

NTRA: Leader in cell-free DNA tests for oncology, women's & organ health. Signatera leads in fast-growing MRD testing. Panorama (NIPT) & Prospera also key. Yrs of investment now driving strong revs & nearing cash flow+. Personalized genetic testing moving to standard of care.

Read full article (1 min)